Dalpiciclib + Letrozole + Leuprorelin

The combination of dalpiciclib, letrozole, and leuprorelin is a treatment regimen used primarily for hormone receptor-positive (HR+) breast cancer. This combination represents a targeted approach that combines a CDK4/6 inhibitor (dalpiciclib) with endocrine therapy (letrozole and leuprorelin). ## Mechanism and Clinical Use This combination works through multiple complementary mechanisms. Dalpiciclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that blocks cell cycle progression. Letrozole is an aromatase inhibitor that reduces estrogen production, while leuprorelin is a gonadotropin-releasing hormone (GnRH) agonist that suppresses ovarian function in premenopausal women[1][4]. Clinical cases have demonstrated rapid and significant responses to this combination therapy in patients with HR+ breast cancer, including those with overwhelming tumor burdens. In reported cases, patients achieved remarkable disease-free periods after treatment initiation[4]. ## Clinical Evidence Several case reports have documented the efficacy of this combination: - Two patients with advanced HR+ postpartum breast cancer (PPBC) showed rapid relief after receiving this combination therapy[1][4]. - Patients with cutaneous tumor metastases showed visible improvement within days of starting treatment[4]. - The combination has shown promise in treating patients who cannot tolerate first-line chemotherapy[3]. ## Safety Profile Common adverse events associated with this combination include: - Neutropenia (including grade 3)[4] - Leukopenia - Potential liver and kidney function effects, though these were within normal ranges in reported cases[4] ## Development Status While dalpiciclib has been studied extensively in combination with letrozole or anastrozole (DAWNA-2 trial), the specific triple combination of dalpiciclib + letrozole + leuprorelin is still being evaluated in clinical practice and case studies rather than large randomized trials[5]. The DAWNA-2 trial demonstrated that dalpiciclib combined with letrozole or anastrozole significantly prolonged progression-free survival compared to endocrine therapy alone in HR+/HER2- advanced breast cancer[5]. ## Related Combinations Similar combinations being studied include: - Dalpiciclib + pyrotinib + letrozole (LORDSHIPS study) for HER2+/HR+ metastatic breast cancer[6] - Trastuzumab + leuprorelin + letrozole + palbociclib for HER2+/HR+ metastatic breast cancer[3] This triple combination represents an emerging approach in precision medicine for breast cancer treatment, particularly for hormone receptor-positive disease.